See the DrugPatentWatch profile for Milnacipran
Milnacipran, marketed under the brand name Savella, is approved in the United States for the management of fibromyalgia [1]. Its availability and approval status in other countries may vary.
When is Savella expected to be available in other countries?
Specific timelines for Savella's availability in countries outside the United States are not readily available. Regulatory approval processes differ by country, which can impact the drug's market entry.
What is the approval status of Savella in Europe?
Savella is not approved for marketing in the European Union. The European Medicines Agency (EMA) has not granted marketing authorization for this indication.
Why is Savella approved for fibromyalgia?
Savella, with its active ingredient milnacipran, is a serotonin-norepinephrine reuptake inhibitor (SNRI). This class of drugs affects neurotransmitters in the brain, which is believed to help manage the widespread pain associated with fibromyalgia [1].
What is the difference between Savella and other fibromyalgia treatments?
Savella works by increasing levels of serotonin and norepinephrine in the central nervous system. Other fibromyalgia treatments may include different classes of medications, such as antidepressants, anticonvulsants, or analgesics, each with distinct mechanisms of action. Non-pharmacological treatments like exercise, physical therapy, and stress management are also common [1].
When does the patent for Savella expire?
Information regarding the specific patent expiry dates for Savella is best accessed through specialized patent tracking resources. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide details on patent status and expiry [2].
Can generic versions of Savella be available?
The availability of generic versions of Savella depends on patent expiry and any subsequent regulatory approvals for generic manufacturers. Once patents expire and regulatory bodies approve generic alternatives, they typically become available, potentially at a lower cost.
What is the clinical data supporting Savella's use?
Clinical trials for Savella demonstrated its efficacy in reducing fibromyalgia pain and improving physical function and global status in patients [1]. These studies are part of the data submitted to regulatory agencies for approval.
Who manufactures Savella?
Savella is manufactured by AbbVie [1].
What are patient concerns regarding Savella?
Patients often have questions about potential side effects, effectiveness for their specific symptoms, and how Savella fits into a broader treatment plan. Common side effects reported include nausea, constipation, insomnia, and headache [1].
Sources:
[1] https://www.savellahcp.com/
[2] https://drugpatentwatch.com/